posted
In this article Dr. Cameron also addresses the CDC’s guidance to ignore any positive IgMs for Lyme disease after the first month of illness.
My comment:
I called LabCorp last week and I was told that physicians can still order a stand alone Western blot. What physicians can no longer order is a stand-alone EIA test. If the EIA is positive, then a Western blot will automatically be run, which was not the case before. If the EIA is negative, a Western blot will not be run, but a physician can still order it separately. So my question is, “are different people being told different things about what this new policy means?” Several patients in my online support groups have said that even before this policy was in place, that they were denied Western blots from LabCorp when their EIAs were negative. I for one would like to see LabCorp make a public statement clarifying their new policy.
In either case, the CDC’s endorsement of the two-tier serology test is the root of the problem here. Patients from Lyme endemic areas already know how the two-tier serology test has failed so many people. Yet the CDC continues to stand behind their flawed studies and support the test. For one, I move to transfer the CDC Lyme office from their isolated enclave in Boulder CO to a Lyme endemic area like Poughkeepsie NY. Then the CDC officers will see for themselves how unreliable the two-tier serology test is, because they will witness their own children, families, friends, and neighbors falling ill with chronic disabling illness, because so few doctors will treat without a positive test.
KarlaL
LABCORP TO DENY PHYSICIANS ACCESS TO WESTERN BLOT TESTS FOR LYME DISEASE
Labcorp will not offer a western blot test for individuals unless they are positive or equivocal for the Enzyme Immunoassay (EIA) or Immunoflorescense (IFA) screening tests for Lyme disease as of August 11, 2014.[1]
Physicians have been disappointed by the poor sensitivity of the EIA or IFA screening tests for Lyme disease. The sensitivity of the whole-cell enzyme-linked immunosorbent assay (ELISA) to the B31 strain typically falls between 33-49% for patients presenting with an EM.[2-4] The sensitivity of the Food and Drug Administration (FDA) approved complement peptide C6 (C6-peptide) was 37% in 89 clinically well-defined individuals with LD [5] and 66.5% 403 sera from patients with an EM rash.[6]
Physicians have commonly ordered the western blot test for Lyme disease even in the absence of positive or equivocal testing. An IgM Western blot test can persist for at least 2 years in individuals with established Lyme disease infection. A IgM WB can persist for months to years in LD even if an individual is treated with antibiotics.[7-9] An IgG can be positive in individuals with a negative screening test.
LabCorp’s decision to deny physician assess to western blot test for Lyme disease only makes testing sensitive than it already is.
It important that LabCorp reverse their position and allow physicians to continue to order western blot tests for Lyme disease even if the EIA and/or IFA are negative. Until then, clinicians may have to direct their patients to other labs.
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic